Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 348
Gene Symbol: APOE
APOE
0.080 GeneticVariation disease BEFREE The ApoE4 allele is associated with increased risk of small vessel disease, which is a cause of vascular cognitive impairment. 30232327 2018
Entrez Id: 348
Gene Symbol: APOE
APOE
0.080 GeneticVariation disease BEFREE Although the association between apolipoprotein E (APOE) genotype and disease progression is well characterized in patients with Alzheimer's disease, such a relationship is unknown in patients with subcortical vascular cognitive impairment. 28507298 2017
Entrez Id: 348
Gene Symbol: APOE
APOE
0.080 Biomarker disease BEFREE APOE4 is significantly associated with dementia and CIND due to AD pathology, but not with VCI. 26923016 2016
Entrez Id: 348
Gene Symbol: APOE
APOE
0.080 GeneticVariation disease BEFREE We previously conducted a systematic review and meta-analysis of all published genetic association studies of sporadic VCI prior to 6 July 2012, which demonstrated that APOE (ɛ4, ɛ2) and MTHFR (rs1801133) variants were associated with susceptibility for VCI. 27314523 2016
Entrez Id: 348
Gene Symbol: APOE
APOE
0.080 GeneticVariation disease BEFREE The relationship between the apolipoprotein E ε4 allele (APOE4) and factors associated with vascular cognitive impairment (VCI) is unclear. 23769398 2013
Entrez Id: 348
Gene Symbol: APOE
APOE
0.080 Biomarker disease BEFREE This systematic study of all published genetic association studies of sporadic VCI supports MTHFR and APOE as susceptibility genes for VCI. 23186985 2013
Entrez Id: 348
Gene Symbol: APOE
APOE
0.080 GeneticVariation disease BEFREE Lower BCRT scores conferred an increased risk of both VCI (OR, 1.75; CI, 1.27-2.42) and AD (OR, 1.86; CI, 1.29-2.67) but attenuated the APOE epsilon4 effect in AD. 16166776 2005
Entrez Id: 348
Gene Symbol: APOE
APOE
0.080 GeneticVariation disease BEFREE In contrast, ApoE epsilon4 allele-bearing individuals had greater risk of having late-onset AD (OR = 8.8; 95% CI 3.7-21.0), or non-vascular cognitive impairment (OR = 7.0; 95% CI 2.5-19.0). 10362893 1999